Use of a dpp-iv inhibitor to reduce hypoglycemic events

Abstract

The invention relates to a method to reduce the hypoglycemic events, especially severe hypoglycemic events resulting from insulin treatment, wherein the patient is treated with a Dipeptidyl peptidase IV inhibitor (DPP-IV inhibitor) or a pharmaceutically acceptable salt thereof.

1 . A method for reducing the hypoglycemic events or severe hypoglycemic events, comprising administering a therapeutically effective amount of a DPP-IV inhibitor or a salt thereof to a patient treated by at least one antidiabetic compound. 
     
     
         2 . A method according to  claim 1 , wherein the DPP-IV inhibitor and the at least one antidiabetic compound are administered simultaneously or sequentially, and in any order. 
     
     
         3 - 8 . (canceled) 
     
     
         9 . A method for reducing hypoglycemic events or severe hypoglycemic events comprising:
 i) selecting a patient treated by at least one antidiabetic compound and showing hypoglycemic episodes, preferably severe hypoglycemic events, and   ii) administering a DPP-4 inhibitor or a salt thereof, in combination with the at least one antidiabetic compound from i), daily, to said patient.   
     
     
         10 - 14 . (canceled) 
     
     
         15 . A method according to  claim 9  wherein the patient is under treatment with an additional one, two or three antidiabetic compounds. 
     
     
         16 . The method of  claim 15 , wherein the additional antidiabetic compound is selected from metformin, nateglinide, glitazones, sulfonylureas, GLP-1 or GLP-1 analogues, and cannabinoid receptor-1 (CB1) antagonists. 
     
     
         17 . The method of  claim 15 , wherein the patient is under treatment with an additional two antidiabetic compounds selected from: metformin and a sulfonylureas, metformin and a glitazone, metformin and a GLP-1 analogue, metformin and a CB1 antagonist, a glitazone and a sulfonylurea, and a GLP-1 analogue and a sulfonylurea. 
     
     
         18 . The method according to  claim 1 , wherein the treated patient is suffering from hyperglycemia, diabetes mellitus, insulin-dependent diabetes mellitus (IDDM), non-insulin-dependent diabetes mellitus (NIDDM), type A insulin resistance, Impaired Glucose Metabolism (IGM), Impaired Fasting Glucose (IFG) or Impaired Glucose Tolerance (IGT). 
     
     
         19 - 21 . (canceled) 
     
     
         22 . A method according to  claim 1 , wherein the hypoglycemic events or severe hypoglycemic events are resulting from treatment with at least one antidiabetic compound. 
     
     
         23 . A method according to  claim 1 , wherein the DPP-IV inhibitor is selected from 1-{2-[(5-cyanopyridin-2-yl)amino]ethylamino}acetyl-2-(S)-cyano-pyrrolidine, vildagliptin, L-threo-isoleucyl thiazolidine, Sitagliptin, GSK23A, saxagliptin, 3-(aminomethyl)-2-isobuthyl-1-oxo-4-phenyl-1,2-dihydro-6-isoquinolinecarboxamide and 2-{[3-(aminomethyl)-2-isobuthyl-4-phenyl-1-oxo-1, 2-dihydro-6-isoquinolyl]oxy}acetamide and optionally in any case pharmaceutical salts thereof. 
     
     
         24 . The method according to  claim 1  wherein between 25 and 200 mg of a DPP-4 inhibitor or a salt thereof, is administered daily. 
     
     
         25 . (canceled) 
     
     
         26 . The method of  claim 16 , wherein the glitazone is pioglitazone or rosiglitazone. 
     
     
         27 . The method of  claim 16 , wherein the GLP-1 analogue is exendin-4.